Aranzazu Diaz de Bustamante

Dr. Aranzazu Diaz de Bustamante


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2021 in Genes
Verified
Journal Article
Open access
PDF file
AAANA ARTECHE
ANA ARTECHE
MRMaria José Gómez Rodríguez
Maria José Gómez Rodríguez
MCMARIA TERESA SANCHEZ CALVIN
MARIA TERESA SANCHEZ CALVIN
JQJuan Francisco Quesada-Espinosa
Juan Francisco Quesada-Espinosa
JRJose Miguel Lezana Rosales
Jose Miguel Lezana Rosales
MAMaria Isabel Alvarez-Mora
Maria Isabel Alvarez-Mora
Autism spectrum disorder (ASD) is a prevalent and extremely heterogeneous neurodevelopmental disorder (NDD) with a strong genetic component. In recent years, the clinical relevance of de novo mutations to the aetiology of ASD has been demonstrated. Current guidelines recommend chromosomal microarray (CMA) and a FMR1 testing as first-tier tests, but there is increasing evidence that support the use of NGS for the diagnosis of NDDs. Specifically in ASD, it has not been extensively evaluated and, thus, we performed and compared the clinical utility of CMA, FMR1 testing, and/or whole exome sequencing (WES) in a cohort of 343 ASD patients. We achieved a global diagnostic rate of 12.8% (44/343), the majority of them being characterised by WES (33/44; 75%) compared to CMA (9/44; 20.4%) or FMR1 testing (2/44; 4.5%). Taking into account the age at which genetic testing was carried out, we identified a causal genetic alteration in 22.5% (37/164) of patients over 5 years old, but only in 3.9% (7/179) of patients under this age. Our data evidence the higher diagnostic power of WES compared to CMA in the study of ASD and support the implementation of WES as a first-tier test for the genetic diagnosis of this disorder, when there is no suspicion of fragile X syndrome.

22 February 2021 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
RGRafael Garcia-Carretero
Rafael Garcia-Carretero
MOM. Olid-Velilla
M. Olid-Velilla
DPD. Perez-Torrella
D. Perez-Torrella
NTN. Torres-Pacho
N. Torres-Pacho
MDM.-T. Darnaude-Ortiz
M.-T. Darnaude-Ortiz
JTJair Antonio Tenorio
Jair Antonio Tenorio

Verified
Journal Article
Open access
PDF file
DPDolores Piniella
Dolores Piniella
ARAnia Canseco Rodriguez
Ania Canseco Rodriguez
SVSilvia Vidal
Silvia Vidal
CXClara Xiol
Clara Xiol
ABAranzazu Diaz de Bustamante
Aranzazu Diaz de Bustamante
FZFrancisco Zafra
Francisco Zafra
In this article, we identified a novel epileptogenic variant (G307R) of the gene SLC6A1, which encodes the GABA transporter GAT-1. Our main goal was to investigate the pathogenic mechanisms of this variant, located near the neurotransmitter permeation pathway, and compare it with other variants located either in the permeation pathway or close to the lipid bilayer. The mutants G307R and A334P, close to the gates of the transporter, could be glycosylated with variable efficiency and reached the membrane, albeit inactive. Mutants located in the center of the permeation pathway (G297R) or close to the lipid bilayer (A128V, G550R) were retained in the endoplasmic reticulum. Applying an Elastic Network Model, to these and to other previously characterized variants, we found that G307R and A334P significantly perturb the structure and dynamics of the intracellular gate, which can explain their reduced activity, while for A228V and G362R, the reduced translocation to the membrane quantitatively accounts for the reduced activity. The addition of a chemical chaperone (4-phenylbutyric acid, PBA), which improves protein folding, increased the activity of GAT-1WT, as well as most of the assayed variants, including G307R, suggesting that PBA might also assist the conformational changes occurring during the alternative access transport cycle.